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Abstract
Historically, organisations have managed product data in a combination of Microsoft Office,
Sharepoint and Document Management Systems. In this paper, we explore how different
technologies can be leveraged to create digital product profiles, and in doing so structure data
to enable effective knowledge management.

Introduction
As with many industries since the pandemic started, the Life Science industry has had to
reinvent itself in a number of different ways, and, while reinventing “ways of working” it also
progressed the development of vaccines and led the charge as the world battled with COVID.
However, before mRNA and viral vectors became conversations at the dinner table, the
industry had already started the “new science” evolution. Personalised medicine, such as cell
and gene therapy, continues to push the industry from treatment-based care to curative.
Similar to the tech start-up model in Silicon Valley, Life Science is being disrupted by new
small and more agile companies. With this disruption the boundaries of innovation are being
expanded at a rate of change that has not been seen before. Chimeric Antigen Receptors,
Oncolytic Virus, Antibody-Drug Conjugates are bio-engineering on new levels.
The Challenge
While it is an incredibly exciting time to be working in the sector, companies are still plagued
by the legacy of being digital laggards. For all of the advances in science, the enabling units
have struggled to keep pace. R&D, Manufacturing and Supply continue to operate in a
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somewhat siloed fashion, and manual processes and procedures are often the default mode
of operation. This tendency to be overly reliant on manual processes is constraining the
business as companies come under pressures with products becoming more complicated to
develop and manufacture. In addition to product complexity, speed to market has been
redefined by the pandemic which has set a benchmark for all future treatments.
As the industry looks forward to a new horizon it needs to look back at an old challenge:
Product Lifecycle Management. To date, as drugs are brought to market, they work through
a series of distinct development phases and business units. From starting out in research,
companies need to consider how products can be developed safely at scale and speed while
ensuring complex regulatory and business requirements are adhered to. Historically,
development and commercialisation processes have not leveraged the full potential of
technology and data. For example, technology transfer is governed via manually executed
procedures and recorded as static word or pdf files in a Data Management System (DMS).
This makes it a challenge for companies to ensure data integrity and to gather business
intelligence.
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Driving forces for PLM & the Digital Thread
Product Lifecycle Management (PLM) and Digital Thread which are both interchangeable, and
are widely adopted frameworks within other industries. The automotive, aviation and
electronics industries have used these concepts to drive transformational changes within
their organisations. While not new to those working in Life Science, their adoption has been
somewhat limited with the exception of medical devices. One of the main reasons for this
being the nature of PLM for biopharmaceutical products is different i.e.
PLM f(x) Product Specifications + Process Design = TPP/QTPP/EC1 → Master Data.

The relationship of product and process data to create target product established conditions
is a level of complexity PLM solutions have not dealt well with previously. These quality
characterisations are imperative to ensure product safety and efficacy. Product profiles are
made up of complex and diverse data sets including materials, equipment, business workflow
etc., a subset of which then needs to be managed as master data to support operational
execution.
From a regulator perspective, ICH Q12 (Technical and Regulatory Considerations for the
Pharmaceutical Product Lifecycle Management – November 2019), and the FDA’s publication
of the Q12 Annex for industry May 2021, are clear indications regulatory and quality
organisations see the potential for PLM to harness the power of process and product data.
The following quote is extracted from the FDA guidance document:

1

TPP = Target Product Profile, QTPP= Quality Target Product Profile, EC = Established Conditions
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“A holistic view of the manufacturing process and control strategy is necessary when
considering Established Conditions since the output of one unit operation is the input
for subsequent operations.”
Given the increasingly complex nature of the business processes, the utilisation of data will
be key to ensuring regulatory compliance. Having a system that can enable users to view and
manage data sets in a business context will not only address the quality requirements, but
also ensure organisations can optimise life cycle activities through research, development,
tech transfer, manufacturing and supply.
The Digital Thread for Life Science is a product and process information framework that
enables users to define and manage all associated data and knowledge to create a digital
product profile.

Practically applying the Digital Thread
The practical application of the digital thread concept in technology transfer enables
companies to specify and manage products and process design in a new and innovative way.
Rather than populate document templates, such as control strategies, process definition,
quality control test plans etc., the digital thread enables the business to record data in a
knowledge management framework.
The image below provides a conceptual overview as to how paper-based tech transfer
compares to a digital thread-based tech transfer.
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The illustrations below provide an overview of product journeys in a pre and post digital
environment.
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By defining the product and process in a digital thread framework, teams are able to
leverage the DTLS platform as a single source of truth. This provides the business with a
series of benefits, as follows:

▪

Enables multiple users to quickly access a broad set of product and process data in
an industry contextualised standard.

▪

The data model automates product genealogy making it easier to identify and track
changes.

▪

Digitising process design enables the creation of templates which can be used to
accelerate fit/gap assessments as products are transferred between sites.

▪

Having defined the product in a digital context it becomes easier to manage changes
through the lifecycle post tech transfer.

▪

The digital thread supports quality management by automating the tracking of
changes and risk management evaluation.

In closing, while the digital thread does not resolve all of the business challenges within
lifecycle management, it is enabling organisations to transition from paper-based business
processes to digital ways of working. By providing tech transfer teams with data frameworks
that automate and simplify tasks, they can focus on higher-value activities. This should
ultimately help companies to use data to drive knowledge.
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